Qiagen NV (QGEN)
43.62
+0.04
(+0.09%)
USD |
NYSE |
May 10, 16:00
43.62
0.00 (0.00%)
After-Hours: 18:58
Qiagen Cash from Financing (TTM): -716.09M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -716.09M |
December 31, 2023 | -433.83M |
September 30, 2023 | -972.76M |
June 30, 2023 | -163.65M |
March 31, 2023 | -124.97M |
December 31, 2022 | -125.80M |
September 30, 2022 | 389.60M |
June 30, 2022 | -94.34M |
March 31, 2022 | -120.17M |
December 31, 2021 | -150.37M |
September 30, 2021 | -212.31M |
June 30, 2021 | -77.21M |
March 31, 2021 | -100.36M |
December 31, 2020 | -50.13M |
September 30, 2020 | -60.04M |
June 30, 2020 | -121.38M |
March 31, 2020 | -149.29M |
December 31, 2019 | -639.08M |
September 30, 2019 | -108.30M |
June 30, 2019 | -148.32M |
March 31, 2019 | -117.80M |
December 31, 2018 | 360.41M |
September 30, 2018 | -66.34M |
June 30, 2018 | 313.47M |
March 31, 2018 | 629.44M |
Date | Value |
---|---|
December 31, 2017 | 387.19M |
September 30, 2017 | 391.21M |
June 30, 2017 | 42.71M |
March 31, 2017 | -251.08M |
December 31, 2016 | -10.60M |
September 30, 2016 | -12.23M |
June 30, 2016 | -0.77M |
March 31, 2016 | -80.23M |
December 31, 2015 | -258.61M |
September 30, 2015 | -299.91M |
June 30, 2015 | -315.50M |
March 31, 2015 | -265.94M |
December 31, 2014 | 192.84M |
September 30, 2014 | 211.56M |
June 30, 2014 | 221.73M |
March 31, 2014 | 247.79M |
December 31, 2013 | -68.76M |
September 30, 2013 | 95.24M |
June 30, 2013 | 103.66M |
March 31, 2013 | 175.25M |
December 31, 2012 | 226.60M |
September 30, 2012 | -162.32M |
June 30, 2012 | -239.78M |
March 31, 2012 | -304.90M |
December 31, 2011 | -310.63M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-972.76M
Minimum
Sep 2023
389.60M
Maximum
Sep 2022
-208.94M
Average
-125.39M
Median
Cash from Financing (TTM) Benchmarks
MoonLake Immunotherapeutics | 530.68M |
LENZ Therapeutics Inc | -- |
Thermo Fisher Scientific Inc | -2.85B |
uniQure NV | 362.72M |
ProQR Therapeutics NV | -2.463M |